Get the latest Science News and Discoveries

Encouraging Phase 1 data for glioblastoma treatment reported by UAB researchers at ASCO - EurekAlert


Preliminary clinical data for glioblastoma multiforme patients enrolled in a Phase 1 clinical trial at the University of Alabama at Birmingham demonstrated that 92 percent of evaluable patients treated with INB-200 exceeded a median progression-free survival of seven months with concomitant temozolomide chemotherapy. The median follow-up was 11.7 months. This survival data along with radiographic improvements are indicative of positive treatment effects, which highlights the potential of IN8bio’s genetically modified, chemotherapy-resistant gamma-delta T cells as a potential first-in-class therapy for patients with newly diagnosed glioblastoma.

None

Get the Android app

Or read this on Eureka Alert

Read more on:

Photo of UAB researchers

UAB researchers

Photo of UAB

UAB

Photo of Encouraging Phase

Encouraging Phase

Related news:

News photo

Aiding the displaced with data

News photo

UAB researchers uncover protein SRSF1’s uncom - EurekAlert

News photo

Travel Through Data From Space in New 3D Instagram Experiences